Innate Pharma Future Growth

Future criteria checks 2/6

Innate Pharma is forecast to grow earnings and revenue by 17.4% and 23.5% per annum respectively while EPS is expected to grow by 108.4% per annum.

Key information

17.4%

Earnings growth rate

108.4%

EPS growth rate

Biotechs earnings growth	35.1%
Revenue growth rate	23.5%
Future return on equity	n/a
Analyst coverage	Good
Last updated	18 Sep 2023

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

MUN:IDDA - Analysts future estimates and past financials data (EUR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	75	-25	13	133	6
12/31/2024	54	-40	-12	27	6
12/31/2023	38	-23	-18	0	5
6/30/2023	52	-63	-33	-32	N/A
3/31/2023	55	-60	-27	-25	N/A
12/31/2022	58	-58	-20	-19	N/A
9/30/2022	57	-40	-24	-23	N/A
6/30/2022	57	-22	-28	-26	N/A
3/31/2022	41	-34	-44	-42	N/A
12/31/2021	25	-45	-60	-58	N/A
6/30/2021	46	-8	-27	-25	N/A
3/31/2021	58	-4	-45	-38	N/A
12/31/2020	70	-1	-63	-52	N/A
9/30/2020	67	-54	-78	-67	N/A
6/30/2020	63	-44	-93	-83	N/A
3/31/2020	75	-33	-62	-24	N/A
12/31/2019	85	8	-30	35	N/A
9/30/2019	108	5	-17	48	N/A
6/30/2019	130	31	-4	61	N/A
3/31/2019	112	17	-19	14	N/A
12/31/2018	94	3	-34	-33	N/A
9/30/2018	70	-19	-49	-46	N/A
6/30/2018	46	-40	-64	-59	N/A
3/31/2018	45	-44	-59	-53	N/A
12/31/2017	44	-48	-54	-48	N/A
9/30/2017	55	-28	-47	-43	N/A
6/30/2017	66	-8	-40	-38	N/A
3/31/2017	66	3	N/A	-37	N/A
12/31/2016	66	13	N/A	-37	N/A
9/30/2016	53	5	N/A	-33	N/A
6/30/2016	41	-2	N/A	-29	N/A
3/31/2016	33	-4	N/A	86	N/A
12/31/2015	25	-7	N/A	202	N/A
9/30/2015	17	-13	N/A	200	N/A
6/30/2015	8	-19	N/A	199	N/A
3/31/2015	8	-19	N/A	91	N/A
12/31/2014	8	-20	N/A	-18	N/A
9/30/2014	11	-15	N/A	-15	N/A
6/30/2014	14	-10	N/A	-12	N/A
3/31/2014	15	-6	N/A	-11	N/A
12/31/2013	17	-3	N/A	-11	N/A
9/30/2013	15	-3	N/A	-12	N/A
6/30/2013	14	-4	N/A	-12	N/A
3/31/2013	14	-3	N/A	-12	N/A
12/31/2012	14	-3	N/A	-11	N/A
9/30/2012	15	-3	N/A	0	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IDDA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IDDA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IDDA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IDDA's revenue (23.5% per year) is forecast to grow faster than the German market (4.6% per year).

High Growth Revenue: IDDA's revenue (23.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IDDA's Return on Equity is forecast to be high in 3 years time

Innate Pharma Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Recent updates

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis Fungoides

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s Lymphoma

Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.

Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023

Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024

Innate Pharma S.A. Provides Update on Lacutamab Clinical Program

Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023

Innate Pharma S.A. Announces Executive Changes

Innate Pharma S.A. Announces Executive Changes

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma

Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung Cancer

Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen Criteria

Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 Congress

Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies

Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies